← All trials
NCT02728102
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2016
- Primary completion
- Aug 1, 2020
- Completion date
- Aug 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 188
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- Center for International Blood and Marrow Transplant ResearchStudy director
- National Cancer Institute (NCI)Collaborator
- National Marrow Donor ProgramCollaborator
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.